Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist
Glucagon-like peptide 1 (GLP-1) receptor agonists have acquired importance in Type 2 diabetes (T2D) treatment due to their glycemic advantages, cardiorenal effects, and favorable body weight. Despite this, the continuous discovery of higher effectiveness treatments is critical to addressing ongoing...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-09-01
|
| Series: | Health Sciences Review |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772632022000216 |